Totally Fun After Sun

Lidocaine Hcl


Mj Products Association, Llc
Human Otc Drug
NDC 72085-145
Totally Fun After Sun also known as Lidocaine Hcl is a human otc drug labeled by 'Mj Products Association, Llc'. National Drug Code (NDC) number for Totally Fun After Sun is 72085-145. This drug is available in dosage form of Gel. The names of the active, medicinal ingredients in Totally Fun After Sun drug includes Lidocaine Hydrochloride - 15 mg/mL . The currest status of Totally Fun After Sun drug is Active.

Drug Information:

Drug NDC: 72085-145
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Totally Fun After Sun
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Lidocaine Hcl
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Mj Products Association, Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Gel
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:LIDOCAINE HYDROCHLORIDE - 15 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Mar, 2018
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 21 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:MJ Products Association, LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:2000538
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0752830606333
UPC stands for Universal Product Code.
UNII:V13007Z41A
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Amide Local Anesthetic [EPC]
Amides [CS]
Antiarrhythmic [EPC]
Local Anesthesia [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
72085-145-08236 mL in 1 BOTTLE (72085-145-08)01 Mar, 2018N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose topical anesthetic

Product Elements:

Totally fun after sun lidocaine hcl aloe vera leaf water carboxypolymethylene ethylhexylglycerin poly(methyl methacrylate; 450000 mw) fd&c yellow no. 5 d&c red no. 7 phenoxyethanol trolamine lidocaine hydrochloride lidocaine lidocaine hydrochloride anhydrous

Indications and Usage:

Indications for the temporary relief of pain and itching due to sunburn, minor skin irritations, minor cuts, minor burns, scrapes and insect bites.

Warnings:

Warnings for external use only do not use in large quantites, particularly over raw or blistered areas. avoid contact with eyes. stop use and ask a doctor if condition gets worse, symptoms last for more than 7 days, or symptoms clear up and occur again with a few days. if sumptoms persist for more than seven days, discontinue use and consult physician. keep out of reach of children. if swallowed, consult physician.

Do Not Use:

Warnings for external use only do not use in large quantites, particularly over raw or blistered areas. avoid contact with eyes. stop use and ask a doctor if condition gets worse, symptoms last for more than 7 days, or symptoms clear up and occur again with a few days. if sumptoms persist for more than seven days, discontinue use and consult physician. keep out of reach of children. if swallowed, consult physician.

Dosage and Administration:

Directions adults and children two-years of age or older: apply to affected area not more than three to four times daily. children under two-years of age: consult a physician.

Stop Use:

Stop use and ask a doctor if condition gets worse, symptoms last for more than 7 days, or symptoms clear up and occur again with a few days. if sumptoms persist for more than seven days, discontinue use and consult physician.

Package Label Principal Display Panel:

Package labeling totally fun after sun

Further Questions:

Questions or comments? contact us directly at 1-888-601-0441 distr. by/par: sunshine & glitter mj products association llc 9750 nw 17th street, miami, fl 33172 www.sunshineglitter.com all rights reserved.


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.